Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204457) titled 'Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old' on Sept. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Outcomes Assessor).
Primary Sponsor: EyeGene Inc.
Condition:
Meningococcal Infections
Intervention:
Biological: EG-MCV4
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: October 2025
Target Sample Size: 1123
Countries of Recruitment:
South Korea
To know more, visit https://clinical...